Compare SSP & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSP | DNA |
|---|---|---|
| Founded | 1878 | 2008 |
| Country | United States | United States |
| Employees | 4600 | 485 |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.7M | 455.8M |
| IPO Year | 1996 | N/A |
| Metric | SSP | DNA |
|---|---|---|
| Price | $4.98 | $10.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $6.95 | ★ $8.50 |
| AVG Volume (30 Days) | 508.1K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,150,585,000.00 | N/A |
| Revenue This Year | $8.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $5.37 |
| 52 Week High | $5.39 | $17.58 |
| Indicator | SSP | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 70.69 |
| Support Level | $3.27 | $9.87 |
| Resistance Level | $5.39 | $11.10 |
| Average True Range (ATR) | 0.29 | 0.72 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 55.05 | 84.84 |
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.